NICE's Exubera problem

The U.K.'s National Institute for Health and Clinical Excellence made one thing perfectly clear in its new draft guidance recommending against use of Exubera inhaled insulin by the National Health Service: patient preferences don't count.

What NICE did not make clear is what kind of proof of clinical and cost effectiveness would convince it to change its mind. But the subtext implies lengthy trials...